

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/019,348	02/05/1998	KATIA GEORGOPOULOS	MGP-042CP2	1925	
26161	7590 01/13/2003		•		
FISH & RICHARDSON PC 225 FRANKLIN ST BOSTON, MA 02110			EXAMINER :		
			NOLAN, PATRICK J		
			ART UNIT	PAPER NUMBER	1
			1644	01	
			DATE MAILED: 01/13/2003	51	

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

09	1019,348
v_l	1011,348

SERIAL NUMBER FILING DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NO.

DATE MAILED:

ART UNIT

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

PAPER NUMBER

The communication filed on **6-13-01** is not fully responsive to the communication mailed 5-9-01 for the reason(s) set forth below.

Specifically, SEQ ID NO. 30, which has now been claimed in base claim 18, has 240 amino acids reported in the Paper Copy of the CRF sent in 6-13-01, however upon review of the chicken sequence in Figure 2, it is clear that SEQ ID NO.30 is disclosed in Figure 2 to have 242 amino acids. Applicant is required to correct said problem and carefully review the new CRF submitted to ensure it matches the disclosed sequences originally filed with the application.

Since the response appears to be <u>bona fide</u>, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is given **ONE** (1) **MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner **Patrick J. Nolan**, Art Unit **1644**, whose telephone number is **703-305-1987**.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

PATRICK J. NOLAN, PH.D PRIMARY EXAMINER

1/13/03

Application No.: 09/0/9,348

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: <u>See Bona Fide Letter</u>
Applicant Must Provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 Patentln Software Program Support (SIRA) Technical Assistance
To Durchago Patentin Software 703 206 2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE